Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11409-11420

  Zhu, Qiuhua ^a   Zhang, Lingxiu ^a   Li, Xiaodong ^a   Chen, Fang ^a   Jiang, Ling ^a   Yu, Guopan ^a   Wang, Zhixiang ^a   Yin, Changxin ^a   Jiang, Xuejie ^a   Zhong, Qingxiu ^a   Zhou, Hongsheng ^a   Ding, Bingjie ^a   Wang, Chunli ^a   Meng, Fanyi ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Kanghua Hospital   (China)

Author keywords

Acute myeloid leukemia; Extramedullary infiltration; EZH2; p ERK p cmyc MMP 2

Indexed keywords

GELATINASE A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; TRANSCRIPTION FACTOR EZH2; UVOMORULIN; EZH2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; EXTRAMEDULLARY INFILTRATION; FEMALE; FLOW CYTOMETRY; HL 60 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOHISTOCHEMISTRY; KASUMI 1 CELL LINE; KG 1ALPHA CELL LINE; LEUKEMIA CELL LINE; LEUKEMIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; U937 CELL LINE; VERY ELDERLY; WESTERN BLOTTING; ACUTE MYELOID LEUKEMIA; BIOSYNTHESIS; CELL MOTION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL MOVEMENT; CHILD; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84961775718     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4983-4     Document Type: Article

References (34)

1. Hiçsönmez G, Çetin M, Tuncer AM, Yenicesu İ, Aslan D, Özyürek E, et al. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment. Leukemia Res. 2004;28:25–34.
2. Rege K, Swansbury GJ, Atra AA, Horton C, Min T, Dainton MG, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77.
3. Chang H, Brandwein J, Yi Q, Chun K, Patterson B, Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Res. 2004;28:1007–11.
4. Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer. 2007;48:393–8.
5. Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15:466–75.
6. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, et al. EZH2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012;120:1107–17.
7. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.
8. Kim SH, Yang WI, Min YH, Ko YH, Yoon SO. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications. Tumor Biol. 2015.
9. Xiaojing Yang RKMK, Miller PBOT: CDKN1C(p57KIP2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells
10. Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 2013;20:667–75.
11. Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Lett. 2013;336:53–60.
12. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003;300:131–5.
13. Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001;112:950–8.
14. Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol. 2011;38:345–53.
15. Cao W, Ribeiro RO, Liu D, Saintigny P, Xia R, Xue Y, et al. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. Plos One. 2012;7:e52984.
16. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. Plos One. 2012;7:e33729.
17. Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling EZH2 expression and epigenetic reprogramming. Cancer Cell. 2013;23:768–83.
18. Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol. 2011;90:643–53.
19. Wu SH, Zheng CP, Xu J. A preliminary study on the relationship between EZH2 and microRNA-101 and the prognostic role of EZH2 in acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2012;33:232–5.
20. Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biol. 2013;34:629–36.
21. Lin Y, Ren L, Xiong H, Du W, Yu Y, Sun T, et al. Role of STAT3 and vitamin D receptor inEZH2-mediated invasion of human colorectal cancer. J Pathol. 2013;230:277–90.
22. Wang C, Chen Z, Li Z, Cen J. The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leukemia Res. 2010;34:1083–90.
23. Shin YJ, Kim J. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. Plos One. 2012;7:e30393.
24. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin a and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114:2733–43.
25. Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, et al. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 2015;117(2):351–62.
26. Lee SCW, Phipson B, Hyland CD, Leong HS, Allan RS, Lun A, et al. Polycomb repressive complex 2 (PRC2) suppresses E-myc lymphoma. Blood. 2013;122:2654–63.
27. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol. 2008;81:112–22.
28. Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp Biol Med. 2012;237:1110–6.
29. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Tetraspanin family member, CD82, regulates expression of EZH2 via inactivation of p38 MAPK signaling in leukemia cells. Plos One. 2015;10:e125017.
30. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011;118:2830–9.
31. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006;5:3096–104.
32. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004;18:1592–605.
33. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol. 1999;105:402–11.
34. Yasuda T. MAP kinase cascades in antigen receptor signaling and physiology. Curr Top Microbiol Immunol. 2015;393:211–31.